Prediction of antidepressant treatment response from gray matter volume across diagnostic categories

Eur Neuropsychopharmacol. 2013 Nov;23(11):1503-15. doi: 10.1016/j.euroneuro.2013.07.004. Epub 2013 Aug 3.

Abstract

Dysfunctional limbic, paralimbic and prefrontal brain circuits represent neural substrates of major depression that are targeted by pharmacotherapy. In a high resolution structural magnetic resonance imaging (MRI) study we investigated the potential of variability of the cortex volume to predict the response to antidepressant treatment among patients with major depression. We enrolled 167 patients participating in the Munich Antidepressant Response Signature (MARS) study and employed voxel based morphometry to investigate covariation of gray matter (GM) maps with changes of depression severity over 5 weeks. Larger left hippocampal and bilateral posterior cingulate GM volumes and lower right temporolateral GM volumes were associated with beneficial treatment response. Subcallosal/orbitofrontal GM volumes were associated with treatment response mainly through gender-by-region interactions. A hippocampal/temporolateral composite marker proved robust in both first episode and recurrent unipolar patients and in bipolar patients. Compared with 92 healthy controls, abnormally low volumes were only detected in the left hippocampal area, particularly in recurrent unipolar patients. These findings indicate that variability of the cortex volume of specific brain areas is associated with different response to antidepressants. In addition, hippocampal findings recursively link together unfavorable treatment response and progressive hippocampal structural changes in recurrent depression.

Keywords: Biomarker; Cingulate cortex; Depression; Hippocampus; Structural magnetic resonance imaging; Treatment response; Voxel based morphometry.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antidepressive Agents / therapeutic use*
  • Atrophy / pathology
  • Case-Control Studies
  • Cerebral Cortex / pathology*
  • Depressive Disorder, Major / diagnosis
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / pathology*
  • Female
  • Humans
  • Hypertrophy / pathology
  • Male
  • Middle Aged
  • Nerve Fibers, Unmyelinated / pathology*
  • Neuroimaging
  • Psychiatric Status Rating Scales
  • Treatment Outcome

Substances

  • Antidepressive Agents